We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Olga Cotaga
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday it expects to report progression-free survival data for the lung cancer randomized MYSTIC trial in mid-2017, and final overall survival data from the trial in 2018 at the latest.
While the focus remains on exploring the benefit of durvalumab and tremelimumab as a combination therapy, the pharmaceutical company will focus the MYSTIC trial on including overall survival and progression-free survival data in durvalumab monotherapy, it said.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
January 17, 2017 02:40 ET (07:40 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
